KANGMEI Group

KANGMEI Group, headquartered in Puning, Jieyang, Guangdong, and Shenzhen, China, is a pharmaceutical company primarily engaged in the production of traditional Chinese medicine and medical equipment, alongside property management services. The company has been publicly traded on the Shanghai Stock Exchange under ticker 600518 since its initial public offering in March 2001. Its market capitalization surpassed 47 billion RMB in 2019, reflecting its substantial scale within the Chinese pharmaceutical sector. Serving healthcare providers and consumers across China, KANGMEI Group faced significant regulatory scrutiny and penalties in 2019 after disclosing false statements within its financial reports, impacting its market standing. The organization was founded in 1997 by Ma Xingtian. Its business model centers on publicly traded on the Shanghai Stock Exchange , generating revenue through production and sales of pharmaceuticals.